Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

NCT05786066 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT05786066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05786066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Recruiting
Start date
April 3, 2023
Completion date
March 31, 2033
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder, depressive disorder, major depressive disorder, post traumatic stress disorder, suicidal ideation